Journal Browser

Journal Browser

New Trends in Biologically Active Compounds in Age-Related Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: 30 July 2024 | Viewed by 960

Special Issue Editor

E-Mail Website
Guest Editor
Instituto CINQUIMA and Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Valladolid, 47011 Valladolid, Spain
Interests: oxidative and nitrative stress; molecular; antioxidants; cancer cell

Special Issue Information

Dear Colleagues,

Age-related diseases are those that are more likely to occur as people age and can be caused by a variety of factors, including exposure to harmful environmental factors and genetic conditions. Some of these diseases include cardiovascular, respiratory, musculoskeletal and neurodegenerative diseases and cancer. Several limiting factors are beneficial for the prevention and treatment of these diseases, such as eating a healthy diet, exercising regularly, not smoking, limiting alcohol consumption, maintaining a healthy weight, controlling blood pressure, cholesterol and diabetes, etc.

Reactive oxygen species (ROS) play an important role in cell function, as when they are produced in excess, they can cause cell damage. Oxidative stress has been linked to a wide range of age-related diseases.

Researchers have been exploring the potential of biologically active compounds (BACs) to combat age-related diseases. BACs are natural or synthetic substances that exhibit biological activity, and they are found in a variety of sources, including plants, animals, and microorganisms.

There are several notable trends in BAC research for age-related diseases:

  1. A focus on specific pathways: Researchers are increasingly targeting specific pathways involved in age-related disease processes. This targeted approach is expected to lead to more effective and safer therapies.
  2. The development of multi-functional BACs: The development of BACs with multiple functionalities is gaining traction. These compounds could address multiple aspects of age-related diseases, potentially offering more comprehensive therapeutic benefits.
  3. Translational research: There is a growing emphasis on translating BAC research into clinical trials. This focus aims to expedite the development of effective therapies for age-related diseases.

Biologically active compounds play a significant role in age-related diseases through various molecular pathways. Here are some key points:

  • “Oxidative Stress and Inflammation”: These are two major pathways leading to senescence. Reactive oxygen species (ROS), AMP-activated protein kinase (AMPK), sirtuins (SIRTs), mammalian target of rapamycin (mTOR), insulin-like growth factor 1 (IGF-1), and p53 are key regulators of metabolic control, connecting aging to the pathways that drive diseases.
  • “Energy Failure”: Mitochondrial dysfunction and deregulated autophagy are also significant contributors to age-related diseases.
  • “Nutrigenomics”: Dietary components have substantive effects on metabolic health. Bioactive molecules capable of selectively modulating specific metabolic pathways affect the development/progression of cardiovascular and neoplastic disease.
  • “Epigenetic Alterations”: Chronic metabolic disorders like obesity and type 2 diabetes share many physiological characteristics with the aging process, such as an increased burden of senescent cells and epigenetic alterations.

These pathways and mechanisms are complex and interconnected, and their understanding can lead to improved diagnostic procedures and therapeutic strategies targeting processes relevant to nutrition and lifestyle.

Future research is expected to focus on addressing these challenges and translating promising BACs into effective therapies for age-related diseases. This could lead to a significant improvement in the quality of life of older adults and reduce the global burden of these diseases.

Prof. Dr. Celia Andrés Juan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • age-related diseases
  • oxidative stress and inflammation
  • energy failure
  • mitochondrial dysfunction
  • deregulated autophagy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


48 pages, 13908 KiB  
Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?
by Celia María Curieses Andrés, José Manuel Pérez de la Lastra, Elena Bustamante Munguira, Celia Andrés Juan and Eduardo Pérez-Lebeña
Int. J. Mol. Sci. 2024, 25(11), 6099; https://doi.org/10.3390/ijms25116099 - 1 Jun 2024
Cited by 2 | Viewed by 628
Michael acceptors represent a class of compounds with potential anti-cancer properties. They act by binding to nucleophilic sites in biological molecules, thereby disrupting cancer cell function and inducing cell death. This mode of action, as well as their ability to be modified and [...] Read more.
Michael acceptors represent a class of compounds with potential anti-cancer properties. They act by binding to nucleophilic sites in biological molecules, thereby disrupting cancer cell function and inducing cell death. This mode of action, as well as their ability to be modified and targeted, makes them a promising avenue for advancing cancer therapy. We are investigating the molecular mechanisms underlying Michael acceptors and their interactions with cancer cells, in particular their ability to interfere with cellular processes and induce apoptosis. The anti-cancer properties of Michael acceptors are not accidental but are due to their chemical structure and reactivity. The electrophilic nature of these compounds allows them to selectively target nucleophilic residues on disease-associated proteins, resulting in significant therapeutic benefits and minimal toxicity in various diseases. This opens up new perspectives for the development of more effective and precise cancer drugs. Nevertheless, further studies are essential to fully understand the impact of our discoveries and translate them into clinical practice. Full article
(This article belongs to the Special Issue New Trends in Biologically Active Compounds in Age-Related Diseases)
Show Figures

Figure 1

Back to TopTop